

Utilization Management and Clinical Medical Policy

Policy Name: Natalizumab agents (Tysabri®, Tyruko®)	Policy Number: MP-RX-FP-97-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Service Category:

- | | |
|--|---|
| ☐ Anesthesia
☐ Surgery
☐ Radiology Procedures
☐ Pathology and Laboratory Procedures | ☐ Medicine Services and Procedures
☐ Evaluation and Management Services
☐ DME/Prosthetics or Supplies
☒ Other: Part B Drugs |
|--|---|

Service Description:

This document addresses the use of *Natalizumab (Tysabri®)*, and *Natalizumab-sztn (Tyruko®)*, approved by the Food and Drug Administration (FDA) as an infused monotherapy for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease or active secondary progressive disease. Natalizumab is also approved to induce and maintain clinical response and remission in adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to conventional Crohn's disease therapies and TNF- α inhibitors.

Background Information:

Natalizumab increases the risk of progressive multifocal leukoencephalopathy (PML). When initiating and continuing treatment, physicians should consider whether the expected benefit is sufficient to offset the risk.

Natalizumab binds to the $\alpha 4$ -subunit of $\alpha 4\beta 1$ and $\alpha 4\beta 7$ integrins expressed on the surface of all leukocytes except neutrophils and inhibits the $\alpha 4$ -mediated adhesion of leukocytes to their 17 counter-receptor(s). The receptors for the $\alpha 4$ family of integrins include vascular cell adhesion molecule-1 (VCAM-1), which is expressed on activated vascular endothelium, and mucosal addressing cell adhesion molecule-1 (MAdCAM-1) present on vascular endothelial cells of the gastrointestinal tract. Disruption of these molecular interactions prevents transmigration of leukocytes across the endothelium into inflamed parenchymal tissue. In vitro, anti- $\alpha 4$ -integrin antibodies also block $\alpha 4$ -mediated cell binding to ligands such as osteopontin and an alternatively spliced domain of fibronectin, connecting segment-1 (CS-1). In vivo, natalizumab may further act to inhibit the interaction of $\alpha 4$ -expressing leukocytes with their ligand(s) in the extracellular matrix and on parenchymal cells, thereby inhibiting further recruitment and inflammatory activity of activated immune cells. The specific mechanism(s) by which TYSABRI exerts its effects in multiple sclerosis and Crohn's disease have not been fully defined. In multiple sclerosis, lesions are believed to occur when activated inflammatory cells, including T-lymphocytes, cross the blood-brain barrier (BBB). Leukocyte migration across the BBB involves interaction between adhesion molecules on inflammatory cells and their counterreceptors present on endothelial cells of the vessel wall. In Crohn's disease, the interaction of the $\alpha 4\beta 7$ integrin with the endothelial receptor MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of the disease. Tysabri (natalizumab) is the reference natalizumab agent; Tyruko (natalizumab-sztn) is biosimilar to Tysabri.

Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous system. Common symptoms of the disease include fatigue, numbness, coordination and balance problems, bowel and bladder dysfunction, emotional and cognitive changes, spasticity, vision problems, dizziness, sexual dysfunction and pain. Multiple sclerosis can be subdivided into four phenotypes: clinically isolated syndrome (CIS), relapsing remitting (RRMS), primary progressive (PPMS) and secondary progressive (SPMS). Relapsing multiple sclerosis (RMS) is a general term for all relapsing forms of multiple sclerosis including CIS, RRMS and active SPMS.

Utilization Management and Clinical Medical Policy

Policy Name: Natalizumab agents (Tysabri®, Tyruko®)	Policy Number: MP-RX-FP-97-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

The treatment goal for multiple sclerosis is to prevent relapses and progressive worsening of the disease. Currently available disease modifying therapies (DMT) are most effective for the relapsing-remitting form of multiple sclerosis and less effective for secondary progressive decline. DMT include injectable agents, infusion therapies and oral agents.

The American Academy of Neurology (AAN) guidelines suggest starting disease-modifying therapy in individuals with relapsing forms of multiple sclerosis with recent clinical relapses or MRI activity. The guidelines also suggest DMT for individuals who have experienced a single clinical demyelinating event and two or more brain lesions consistent with multiple sclerosis if the individual wishes to start therapy after a risks and benefits discussion. The guidelines do not recommend one DMT over another. However, some DMTs were recommended for certain multiple sclerosis subpopulations, including a recommendation for natalizumab for highly active disease.

Crohn's disease is a chronic, relapsing inflammatory bowel disease affecting the gastrointestinal mucosa. Fistula formation, fissuring, discontinuous intestinal and transmural involvement with bowel-wall thickening and extraintestinal manifestations including arthritis, skin and eye manifestations, metabolic deficiencies, hypercoagulation and hepatobiliary disease are frequent complications. Treatment options include 5-ASA products, glucocorticoids, antibiotics, immunosuppressive drugs, methotrexate and targeted immune modulator agents.

Natalizumab has a black box warning for progressive multifocal leukoencephalopathy (PML). Natalizumab increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include duration of therapy, prior use of immunosuppressants and presence of anti-JCV antibodies. Monitor patients and withhold Tysabri immediately at the first sign or symptom suggestive of PML. Because of this safety concern, natalizumab has been generally reserved for individuals who have had an inadequate response or are unable to tolerate alternate therapies for multiple sclerosis or Crohn's disease. Natalizumab is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH Prescribing Program

Approved Indications

- A. Multiple Sclerosis (MS)
- B. Crohn's Disease (CD)

Other Uses

- A. None.

Utilization Management and Clinical Medical Policy

Policy Name: Natalizumab agents (Tysabri®, Tyruko®)	Policy Number: MP-RX-FP-97-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Natalizumab agents (Tysabri®, Tyruko®)

- A. Criteria For Initial Approval** (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met **all** approval criteria.*)

Initial requests for Natalizumab agents (Tysabri, Tyruko) may be approved if the following criteria are met:

- i. Individual has a diagnosis of relapsing multiple sclerosis (RMS) (including clinically isolated syndrome, relapsing-remitting disease or active secondary progressive disease); **AND**
- ii. Individual is enrolled in and meeting all conditions of the MS Touch Prescribing Program; **OR**
- iii. Individual has a diagnosis of moderate to severe Crohn's disease (CD) with evidence of inflammation and is using Tysabri for induction and maintenance of clinical response and remission; **AND**
- iv. Individual has had an inadequate response to or is unable to tolerate conventional Crohn's disease therapies and TNF- α inhibitors; **AND**
- v. Individual is enrolled in and meeting all conditions of the CD Touch Prescribing Program; **AND**
- vi. Individual has had a John Cunningham virus (JCV) antibody test and the results as well as risks and benefits have been discussed and understood.

B. Criteria For Continuation of Therapy

Continuation requests for (Tysabri®, Tyruko®) may be approved if the following criteria are met:

- i. Progress notes or clinical documentation from the prescriber confirms that the patient requires continued treatment and has demonstrated stabilization and/or improvement in disease activity; **AND**
- ii. There is no evidence of treatment-limiting adverse effects associated with natalizumab.

C. Authorization Duration

- i. Initial Approval Duration: Up to 12 months
- ii. Reauthorization Approval Duration: Up to 12 months

D. Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

Natalizumab (Tysabri) or natalizumab-sztn (Tyruko) may not be approved for the following:

- i. Individual is using to treat primary progressive multiple sclerosis; **OR**

Utilization Management and Clinical Medical Policy

Policy Name: Natalizumab agents (Tysabri®, Tyruko®)	Policy Number: MP-RX-FP-97-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

- ii. Individual is using to treat non-active secondary progressive multiple sclerosis; **OR**
- iii. Individual is currently responsive to and tolerating another treatment for multiple sclerosis or Crohn's disease; **OR**
- iv. Individual has a current or prior history of progressive multifocal leukoencephalopathy (PML); **OR**
- v. Individual has a medical condition which significantly compromises the immune system including HIV infection or AIDS, leukemia, lymphoma or organ transplantation; **OR**
- vi. Use in combination with chronic antineoplastics, immunosuppressants (for example, azathioprine) or TNF- α inhibitors; **OR**
- vii. Use in combination with other MS disease modifying agents s (including Aubagio, Avonex, Bafiertam, Betaseron, Briumvi, Copaxone/Glatiramer/Glatopa, Extavia, Gilenya, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ocrevus Zunovo, Plegridy, Ponvory, Rebif, Tasenso ODT, Tecfidera, Vumerity and Zeposia); **OR**
- viii. May not be approved when the above criteria are not met and for all other indications.

Utilization Management and Clinical Medical Policy

Policy Name: Natalizumab agents (Tysabri®, Tyruko®)	Policy Number: MP-RX-FP-97-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Limits or Restrictions:

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

- i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Recommended Dosage	Limit
Natalizumab (Tysabri) inj. 300 mg/15 mL single-use vial	• 300 mg IV every four weeks.	1 vial per 28 days
Natalizumab-sztn (Tyruko) inj. 300 mg/15 mL single-dose vial	• 300 mg IV every four weeks.	1 vial per 28 days

Utilization Management and Clinical Medical Policy

Policy Name: Natalizumab agents (Tysabri®, Tyruko®)	Policy Number: MP-RX-FP-97-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

ICD-10 Diagnostic Codes:

Codes	Description
G35.A	Relapsing-remitting multiple sclerosis
G35.C1	Active secondary progressive multiple sclerosis
G37.9	Demyelinating disease of central nervous system, unspecified [clinically isolated syndromes]
K50.00-K50.919	Crohn's disease [regional enteritis]
Z01.84	Encounter for antibody response examination

HCPCS Codes:

Codes	Description
J2323	Injection, natalizumab, 1 mg [Tysabri]
Q5134	Injection, natalizumab-sztn (Tyruko), biosimilar, 1 mg

Utilization Management and Clinical Medical Policy

Policy Name: Natalizumab agents (Tysabri®, Tyruko®)	Policy Number: MP-RX-FP-97-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Reference Information:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
2. Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. *Lancet Neurol.* 2012; 11:420-28. DOI: [http://dx.doi.org/10.1016/S1474-4422\(12\)70056-X](http://dx.doi.org/10.1016/S1474-4422(12)70056-X).
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
5. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 2018; 90: 777-788. Available from: <https://www.aan.com/Guidelines/home/GuidelineDetail/898>. Accessed: January 4, 2023
6. TYSABRI (natalizumab) injection, for intravenous use: Prescribing information. Revised March 2025. Accessed June 8, 2026.
7. TYRUKO (natalizumab-sztn) injection, for intravenous use: Prescribing information. Accessed June 8, 2026.
8. UpToDate, Inc. Natalizumab (including biosimilars): Drug information. UpToDate. Accessed June 8, 2026.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Utilization Management and Clinical Medical Policy

Policy Name: Natalizumab agents (Tysabri®, Tyruko®)	Policy Number: MP-RX-FP-97-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	---	---	--	---

Policy History:

Type of Review	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review 6/8/2026	Coding Update: Removed ICD-10-CM G35 and added G35.A, G35.C1, and G37.9. dded recommended dosage and updated reference information. Administrative update to incorporate new policy template.	8/14/2026	8/19/2026
Annual Review 9/2/2025	Minimal changes; word formatting. Add Ocrevus Zunovo to exclusion for concurrent use with other disease modifying therapy criteria. Coding Reviewed: No changes.	9/5/2025	9/16/2025
Annual Review 9/27/2024	Add sections: approved indications, other uses, criteria for continuation therapy, approval duration, therapeutic alternatives. Add Briumvi and Tascenso ODT to exclusion for concurrent use with other disease modifying therapy criteria. Add Tyruko into natalizumab clinical criteria; add quantity limit. Align Crohn's disease wording with criteria for other Crohn's disease agents. Added HCPCS Q5134. Removed HCPCS J3490, J3590.	3/14/2025	4/2/2025
Policy Inception	9/27/2023 Elevance Health's Medical Policy adoption.	N/A	11/30/2023